MTOR and central nervous system cancer: 2-hydroxyglutarate (2HG) produced by IDH1/2 mutation promotes mTOR activity by depleting KDM4A and decreasing DEPTOR protein stability (128), presenting another mechanism of IDH1/2 mutation promoting the genesis of glioma and the possibility of a combination IDH inhibitor and mTOR inhibitor.